In the published article, there was an error in the author list, and author Anwen Liu and Zhimin Zeng was erroneously excluded. The corrected author list appears below.
Zhimin Zeng1,2,3†, Xiaoying Qian4,5†, Fanrong Liu6†, Yong Wang4,5, Yong Yuan7, Chen Fang4,5, Xinwei Zhang4,5, Shangkun Yuan4,5, Renfang Chen4,5, Biao Yu4,5, Tong Wang4,5, Yan Yin8, Yong Li4,5* and Anwen Liu1,2,3*
The Author contributions have also been amended to: AL and YL co-designed the research. ZZ, XQ, and FL made a significant contribution to the data integration and analysis. ZZ provided patients’ information and data analysis. XQ drew up the manuscript. FL and YW processed the figures and tables. YYu, CF, XZ, and SY collected the outcome. RC, BY, TW and YYi followed up on the case. All authors contributed to the article and approved the submitted version.
In the published article, there was an error. The approval of the institutional ethics committee of Second Affiliated Hospital of Nanchang University was not added to the ethics statement.
A correction has been made to Ethics statement. This sentence previously stated:
“This study was reviewed and approved by the Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University”.
The corrected sentence appears below:
“This study was reviewed and approved by the institutional ethics committee of the Second Affiliated Hospital of Nanchang University and the Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
pulmonary sarcomatoid carcinoma, immune checkpoint inhibitors, immunotherapy, anlotinib, camrelizumab, tislelizumab
Citation
Zeng Z, Qian X, Liu F, Wang Y, Yuan Y, Fang C, Zhang X, Yuan S, Chen R, Yu B, Wang T, Yin Y, Li Y and Liu A (2023) Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma. Front. Immunol. 14:1269596. doi: 10.3389/fimmu.2023.1269596
Received
30 July 2023
Accepted
24 August 2023
Published
06 September 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
14 - 2023
Updates
Copyright
© 2023 Zeng, Qian, Liu, Wang, Yuan, Fang, Zhang, Yuan, Chen, Yu, Wang, Yin, Li and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anwen Liu, awliu666@163.com; Yong Li, liyongcsco@email.ncu.edu.cn
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.